Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that it has voluntarily paused screening and...

Related Keywords

Tokyo ,Japan ,North Carolina ,United States ,South San Francisco ,California ,San Francisco ,Kenji Yasukawa ,Nathan Bachtell ,Drug Administration ,Data Monitoring Committee ,Liver Advisory Panel ,Astellas Pharma Inc ,European Medicines Agency ,Astellas Center ,Development At Astellas ,Audentes Therapeutics Inc ,Astellas Pharma ,X Linked Myotubular Myopathy ,Investigational New Drug ,Senior Vice President ,Gene Therapy ,Astellas Medical Monitor ,X Linked Myotubular ,Regenerative Medicine ,Advanced Therapy ,Rare Pediatric Disease ,Fast Track ,Orphan Drug ,Priority Medicines ,Audentes Therapeutics ,Focus Area Approach ,